Literature DB >> 10955329

Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.

R J Cook1, D D Gladman, D Pericak, M B Urowitz.   

Abstract

OBJECTIVE: To identify predictors of short term mortality in systemic lupus erythematosus (SLE) in terms of time dependent clinical indicators of disease activity from the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
METHODS: We studied data collected on patients followed at the University of Toronto Lupus Clinic. Clinical and laboratory indicators of disease activity are recorded at each clinic visit and a SLEDAI summary score is calculated. Survival analyses were conducted in which the prognostic value of the time dependent indicators of disease activity was examined on 6-month mortality through a multivariate Cox regression model. Relative risks, confidence intervals, and significance levels were obtained for each indicator to reflect their clinical importance and statistical significance.
RESULTS: The sample consisted of 806 patients followed for a median of 6.6 years; 702 (87%) were female, 671 (83%) were Caucasian, and the mean age at first clinic visit was 36 years. Seventy-two patients died within 6 months of their last clinic visit. In a univariate regression model, a categorical variable reflecting total SLEDAI score was highly prognostic for mortality (p < 0.001) and yielded increasing relative risks of 1.28 for SLEDAI 1-5 vs 0, 2.34 for SLEDAI 6-10 vs 0, 4.74 for SLEDAI 11-19 vs 0, and 14.11 for SLEDAI > 20 vs 0. In a separate multivariate Cox model examining the individual components of SLEDAI, presence of organic brain syndrome, retinal changes, cranial nerve involvement, proteinuria, pyuria, pleurisy, fever, thrombocytopenia, and leukopenia each significantly increased the risk of death, while new rash and anti-DNA antibodies conferred protective effects.
CONCLUSION: This time dependent Cox regression analysis identified the extent to which SLE disease activity, revealed by SLEDAI, is prognostic for short term mortality. Further, important individual components were identified and their prognostic value for death was estimated.

Entities:  

Mesh:

Year:  2000        PMID: 10955329

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  35 in total

1.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.

Authors:  Yuan An; Yunshan Zhou; Liqi Bi; Bo Liu; Hong Wang; Jin Lin; Danyi Xu; Mei Wang; Jing Zhang; Yongfu Wang; Yan An; Ping Zhu; Ronghua Xie; Zhiyi Zhang; Yifang Mei; Xiangyuan Liu; Xiaoli Deng; Zhongqiang Yao; Zhuoli Zhang; Yu Wang; Weiguo Xiao; Hui Shen; Xiuyan Yang; Hanshi Xu; Feng Yu; Guochun Wang; Xin Lu; Yang Li; Yingnan Li; Xiaoxia Zuo; Yisha Li; Yi Liu; Yi Zhao; Jianping Guo; Lingyun Sun; Minghui Zhao; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-11-28       Impact factor: 2.980

3.  Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.

Authors:  Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Inflamm Res       Date:  2016-02-26       Impact factor: 4.575

4.  Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study.

Authors:  Carlos A Roldan; Joseph Joson; Janeen Sharrar; Clifford R Qualls; Wilmer L Sibbitt
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

5.  Patient-Reported Outcomes Predict Mortality in Lupus.

Authors:  Desiree R Azizoddin; Meenakshi Jolly; Shilpa Arora; Ed Yelin; Patricia Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-13       Impact factor: 4.794

Review 6.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 7.  Overview of pathophysiology and treatment of human lupus nephritis.

Authors:  Kimberly Trotter; Marcus R Clark; Vladimir M Liarski
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

8.  Novel evidence-based systemic lupus erythematosus responder index.

Authors:  Richard A Furie; Michelle A Petri; Daniel J Wallace; Ellen M Ginzler; Joan T Merrill; William Stohl; W Winn Chatham; Vibeke Strand; Arthur Weinstein; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

9.  Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.

Authors:  Ghada Boghdadi; Enass A Elewa
Journal:  Rheumatol Int       Date:  2014-04-21       Impact factor: 2.631

Review 10.  [Immunoablation followed by autologous stem cell transplantation in lupus: a clinical update].

Authors:  T Alexander; R Arnold; F Hiepe
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.